🎁
DIWALI SPECIAL

20% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
SYNCOM FORMU (I)

SYNCOM FORMU (I) Latest Share Price (SYNCOMF)

₹20.41
0.08+0.39%
Overall Score72/100
Day range20
₹20.41
21
52-week10
₹20.41
27
Above low+99.9%
Below high25.8%
Range position59%
Open20.33
Prev Close20.33
Bid20.392.5K
Ask20.441.6K

TODAY IN ONE LINE

SYNCOMF edged up 0.4% on above-average volume (3.7x avg), in line with Nifty's 1.1% move.

With a market cap of ₹1,920.42 Cr., it trades at a P/E of 22.45. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume6.3M−68%vs 20D avg
Price Band20
Lower Band17.66
Upper Band26.48
Tick Size0.01
Daily Volatility3.16%
Annualised Vol60.37%
Market Cap₹1,920.42 Cr.
Promoter50.57%
Face Value₹1
Fwd P/E—
PEG0.32
EV/EBITDA8.66
P/S2.69
ROA9.36%
Beta1.24
Div Payout—
THE STOCK SCORE
Overall Score72/100
Updated 07 Sept

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

SYNCOM FORMU (I) flags & news 

Key strengths, potential risks, and recent updates.

✅ 9 green flags🚩 0 red flags

Green Flags

  • ●Earnings GrowthEPS (TTM) grew by a solid 68.8% YoY
  • ●High Capital EfficiencyROCE of 18.6% indicating pricing power
  • ●Strong Return on EquityHealthy ROE of 18.4%
  • ●Healthy Operating MarginsOPM is structurally strong at 20.9%
  • ●Reasonable ValuationTrading at a moderate P/E of 17.8x
  • ●High Promoter HoldingPromoters hold 50.6% skin-in-the-game
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●FII AccumulationFII holding increased by 1.87% QoQ
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

No red flags identified

Latest SYNCOM FORMU (I) News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

SYNCOM FORMU (I) valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for SYNCOM FORMU (I), framed against the sector median so the premium or discount is obvious at a glance.

SYNCOM FORMU (I) trades at a P/E of 22.45× and P/B of 4.63×.

Key MetricsMarket + reported · 29 Oct 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹1,920.42 Cr.
P/E Ratio
22.45
P/B Ratio
4.63
EPS
₹0.26
Profitability

Profitability

ROE
18.42%
ROCE
18.57%
Net Margin
15.63%
Op Margin
20.91%
Growth

Growth

EPS YoY
68.8%
Revenue YoY
-9%
Qtr Sales
—
Qtr Profit
—
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹4.41
Div Yield
0.49%
Promoter Holding
50.57%
Technicals

SYNCOM FORMU (I) technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SYNCOM FORMU (I) — derived from the latest tape, not yesterday's close.

SYNCOM FORMU (I) last traded at ₹20.41 with an intraday range of ₹20.02–₹20.51 — latest indicator, pivot and CPR signals below.

Last updated: 30 October 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹20.41
LevelPrice (₹)Distance% Δ
R421.59+1.18+5.77%
R321.10+0.69+3.36%
R220.80+0.39+1.93%
R120.61+0.20+0.96%
PIVOT20.31-0.10-0.47%
CURRENT20.41——
S120.12-0.29-1.44%
S219.82-0.59-2.87%
S319.63-0.78-3.84%
S419.14-1.27-6.24%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 20.27P: 20.31TC: 20.36
R1
R2
R3
R4
indicator
LTP: 20.41
PDH: 20.90
PDL: 20.16
● Market Sentiment

SYNCOMF is trading Above CPR, indicating Bullishness

● CPR Width

CPR is Average

● Opening Range

Day's range: ₹20.07–₹20.51

● Price Position

Trading Inside opening range

Financials

SYNCOM FORMU (I) financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for SYNCOM FORMU (I) — consolidated or standalone — with margins, YoY growth and key ratios inline.

SYNCOM FORMU (I) reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,920.42 Cr. and reported EPS of ₹0.26.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026May 2026
Revenue from Operations489
489
▲ 0.0%
Sales Growth YoY %Derived5.20%
5.20%
Other Income31
31
▲ 0.0%
Total Income521
521
▲ 0.0%
284
284
▲ 0.0%
Gross ProfitDerived205
205
▲ 0.0%
Gross Margin %Derived41.89%
41.89%
127
127
▲ 0.0%
EBITDA (Operating Profit)Derived77
77
▲ 0.0%
OPM %Derived15.83%
15.83%
8
8
▲ 0.0%
Profit Before Tax (PBT)101
101
▲ 0.0%
25
25
▲ 0.0%
Effective Tax %Derived24.41%
24.41%
Total Profit for Period76
76
▲ 0.0%
Net Profit (Owner's PAT)Derived76
76
▲ 0.0%
Net Profit Margin %Derived15.63%
15.63%
PAT Growth YoY %Derived54.62%
54.62%
Earnings Per Share (EPS ₹)0.81
0.81
▲ 0.0%
Diluted Shares Outstanding (Cr)94
94
▲ 0.0%
Other Comprehensive Income (Net of Tax)-4
-4
▲ 0.0%
Total Expenses (incl. D&A & Interest)419
419
▲ 0.0%
Material Cost % of RevenueDerived45.17%
45.17%
Employee Cost % of RevenueDerived13.71%
13.71%
Other Cost % of RevenueDerived12.34%
12.34%
Interest Coverage (x)Derived61.38x
61.38x
Sales CAGR · 3Y
+1.7%
Sales CAGR · 5Y
+13.2%
PAT CAGR · 3Y
+15.6%
PAT CAGR · 5Y
+24.7%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

SYNCOM FORMU (I) segment analysis : revenue and profit mix.

Disclosed business segments at SYNCOM FORMU (I) with their share of revenue and profit, switchable between consolidated and standalone reporting.

SYNCOM FORMU (I) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for SYNCOM FORMU (I).

Our AI distills the core fundamental drivers supporting SYNCOM FORMU (I), the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 29 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Return-quality risk. ROE below 13% would indicate weaker capital compounding.

  • Income thesis breaks if the dividend is cut or yield falls below 0.24%.

Shareholding

SYNCOM FORMU (I) shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in SYNCOM FORMU (I) — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Promoters50.57%
Public47.20%↓1.88%
FII2.22%↑1.87%

Ownership Distribution

Promoters
50.57%
Retail & Public
47.20%
Foreign Institutions
2.22%

Category Trends

Foreign Institutions Breakdown
Total Holding: 2.22%
Net Change: +1.87%
Category Total2.22%
Total Holding2.22%
Net Change+1.87%
Aggregate Data
Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod

Foreign Institutions: 2.22%

Individual institutional breakdown is not disclosed by the company, but aggregate holding data is shown above.

💡 This category has 2.22% total holding without detailed institution-wise disclosure
Peers

SYNCOM FORMU (I) peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SYNCOM FORMU (I) is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SUN PHARMACEUTICAL IND L
₹4.23 Lakh Cr
Best Profit Growth
ONESOURCE SPECL PHARMA L
443.77 %
Highest Dividend Yield
SANOFI INDIA
4.10 %

Peer Comparison

Company Name
09 · Chart Patterns

SYNCOM FORMU (I) chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for SYNCOM FORMU (I) — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

SYNCOM FORMU (I) delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for SYNCOM FORMU (I) over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in SYNCOM FORMU (I) stood at 26.7% of traded volume, against a 20-day average of 27.9%.

Avg Delivery (20D)27.9%-1.2 ppt latest vs avg
Highest Delivery40.6%on 08 Oct
Avg Volume (20D)2.00 Cr20-day run-rate
Conviction Trend↓ Weakening-1.2 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

SYNCOM FORMU (I) announcements: results, concalls, ratings, M&A.

Filings SYNCOM FORMU (I) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

SYNCOM FORMU (I) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 75 documents below.

  1. 08 Oct 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018View PDF

    Certificate under SEBI (Depositories and Participants) Regulations, 2018

    Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  2. 01 Oct 2026General UpdatesView PDF

    General Updates

    Syncom Formulations (India) Limited has informed the Exchange about General Updates

  3. 01 Oct 2026Change in ManagementView PDF

    Change in Management

    Syncom Formulations (India) Limited has informed the Exchange about change in Management

  4. 01 Oct 2026General UpdatesView PDF

    General Updates

    Syncom Formulations (India) Limited has informed the Exchange about General Updates

  5. 01 Oct 2026Shareholders meetingView PDF

    Shareholders meeting

    Syncom Formulations (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026.…

Corporate Actions

SYNCOM FORMU (I) dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue SYNCOM FORMU (I) has declared, sequenced by announce and record date.

SYNCOM FORMU (I) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About SYNCOM FORMU (I): business, sector, key facts.

What SYNCOM FORMU (I) does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

SYNCOM FORMU (I) operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SYNCOMF, BSE: 524470.

SYNCOMF
Healthcare

SYNCOM FORMU (I)

NSE · SYNCOMF·BSE · 524470·www.syncomformulations.com

Syncom Formulations (India) Limited is a pharmaceutical company primarily focused on the manufacturing, marketing, and sale of pharmaceutical formulations within India. Their operations are structured across three key segments: manufacturing and dealing in pharmaceutical drugs and formulations, trading of commodities, and renting of properties. The core of their business lies in the production and distribution of a wide array of pharmaceutical products.

Their pharmaceutical product portfolio is extensive and covers various therapeutic areas. This includes antibiotics and anti-infectives to combat bacterial infections, anthelmintics for parasitic worm infestations, antimalarial drugs for malaria treatment, and medications targeting cardiac (heart-related) conditions. Beyond these, they offer formulations for dermatological (skin), gastrointestinal, gynecological, ophthalmological (eye), orthopedic, and pediatric applications. This broad range of offerings demonstrates a commitment to providing solutions across a diverse spectrum of healthcare needs.

In addition to their core pharmaceutical offerings, Syncom Formulations also markets and distributes a line of health and wellness products under the Cratus brand. These products, categorized as life care, evolve, and right nutrition products, likely represent an effort to expand their reach beyond prescription medications and cater to a broader consumer base interested in preventative healthcare and supplementary nutrition. This diversification strategy allows them to engage a wider segment of the market.

The company’s operational scope extends beyond pharmaceutical manufacturing and sales. They actively engage in the trading of commodities, suggesting involvement in the procurement of raw materials and potentially other related goods. Further, the renting of properties indicates a supplementary income stream, possibly through the ownership of facilities used in their operations or through independent real estate holdings. This diversification mitigates risk and provides additional revenue streams.

Syncom Formulations distributes its products in various dosage forms, showcasing a commitment to offering flexible and convenient treatment options for patients. These forms include tablets, capsules, ointments, injections, oral liquids, and effervescent formulations, reflecting adaptability to the needs of different medical conditions and patient preferences. The company also exports its products, demonstrating a presence in international markets beyond India’s borders.

company facts
Employees—
SectorHealthcare
HeadquartersIndore, India
Market Cap₹1,920.42 Cr.
Listed OnNSE
leadership22 on record
Mr. Ankit Jain
Additional Non-Executive Independent Director
Mr. Ankit Kedarmal Bankda
Executive Chairman
Mr. Ankur Vijay Bankda
Chief Financial officer & President of Export Marketing
Mr. Ankur Vijay Bankda
President of Export Marketing
Mr. Kedarmal Shankarlal Bankda M.Com
Whole-Time Director
Mr. Rahul Vijay Bankda
CFO & President of Domestic Marketing
Mr. Rahul Vijay Bankda
Managing Director & Director
Mr. Rahul Vijay Bankda
President of Domestic Marketing
Mr. Rakesh Chandra Srivastava
Chief Marketing Officer
Mr. Ritesh Lunkad
Additional Non-Executive Independent Director
Mr. Vijay Shankarlal Bankda B. Com LLB
MD and Executive & Non Independent Director
Ms. Payal Ankur Bankda
Vice President of Human Resources
§ ∞ · Plainly Answered

Questions investors ask about SYNCOM FORMU (I) (SYNCOMF).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of SYNCOM FORMU (I) (SYNCOMF)?

The current share price of SYNCOM FORMU (I) (SYNCOMF) is ₹20.41. Today, the stock has gained by ₹0.08 (0.39%), trading in a range of ₹20.02 to ₹20.51. The stock opened at ₹20.33 with a trading volume of 63,33,438 shares.

02Is SYNCOM FORMU (I) stock a good investment for long-term?

SYNCOM FORMU (I) can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,920.42 Cr., P/E ratio of 22.45, ROE of 18.42%, and ROCE of 18.57%. The dividend yield stands at 0.49%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of SYNCOM FORMU (I) stock?

The 52-week high price of SYNCOM FORMU (I) (SYNCOMF) is ₹27.49, while the 52-week low is ₹10.21. Currently trading at ₹20.41, the stock is 99.9% above its 52-week low and 25.75% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy SYNCOM FORMU (I) stock at the current price?

Whether to buy SYNCOM FORMU (I) stock at ₹20.41 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.45 and P/B ratio of 4.63. Today's performance shows a gain of 0.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of SYNCOM FORMU (I) and when is the next dividend?

SYNCOM FORMU (I) offers a dividend yield of 0.49%, which means for every ₹100 invested at the current price of ₹20.41, you can expect to receive approximately ₹0.49 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of SYNCOM FORMU (I)?

SYNCOM FORMU (I)'s key financial metrics include: P/E Ratio: 22.45, P/B Ratio: 4.63, ROE: 18.42%, ROCE: 18.57%, Dividend Yield: 0.49%, EPS: ₹0.26, Book Value: ₹4.41, and Debt-to-Equity: 0. The company's market cap stands at ₹1,920.42 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is SYNCOM FORMU (I) stock performing today in the market?

SYNCOM FORMU (I) stock opened at ₹20.33 and is currently trading at ₹20.41, showing a gain of ₹0.08 (0.39%). The intraday high is ₹20.51 and low is ₹20.02. The trading volume stands at 63,33,438 shares, indicating strong market participation today.

08What is the P/E ratio of SYNCOM FORMU (I) and what does it indicate?

SYNCOM FORMU (I) has a Price-to-Earnings (P/E) ratio of 22.45, which means investors are willing to pay 22.45 for every ₹1 of earnings. With an EPS of ₹0.26, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about SYNCOM FORMU (I) (SYNCOMF) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.